How much of Novavax’s revenue comes from haram?
Novavax develops vaccines to prevent serious infectious diseases and address urgent global health needs. The company’s vaccine candidates include NVX-CoV2373, a coronavirus vaccine; NanoFlu, a nanoparticle seasonal influenza vaccine; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine.
Novavax earns its revenue primarily from the following revenue sources:
- Government Contracts:
Includes revenue generated from engaging in R&D services under U.S. government contracts and grants.
- Grants and Other:
Includes revenue generated from collaborations, license agreements, and funding arrangements with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the clinical development and manufacturing of NVX-CoV2373.
- Royalties:
Includes royalty revenues earned from SK bioscience’s sale of the antigen component of NVX-CoV2373 to the Korean government.
The contributions from each of Novavax’s revenue segments in their Q2 2021 report were as follows:
Practical Islamic Finance concludes:
None of Novavax’s revenue comes from anything inherently haram.
Does Novavax rely on interest to operate?
[wbcr_php_snippet id=”11367″]
What is Novavax Environmental, Social, and Governance (ESG) Impact?
Environment
No notable environmental highlights.
Social
Novavax has a Glassdoor rating of 3.9 out of 5 from over 110 current and previous employees compared to a 3.3 average for all other Glassdoor rated companies.
Governance
No notable governance highlights.
Practical Islamic Finance concludes:
Novavax has a net positive ESG impact.
Comfort Rating
From Novavax’s business, financial, and ESG reviews, Practical Islamic Finance rates Novavax stock as: